Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fatty Acid

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    160 result(s) found for: Fatty Acid. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2005-002386-37 Sponsor Protocol Number: IVN3ICD Start Date*: 2007-08-24
    Sponsor Name:Department of Cardiology, Aalborg Hospital
    Full Title: Intravenous infusion of n-3 polyunsaturated fatty acids and ventricular tackycardi in patients with implantable cardioverter defibrillator (ICD)
    Medical condition: Patients with an implantable cardioverter defibrillator (ICD-unit) for treatment for cardiac ventricular arrhythmias and for prevention of sudden cardiac death
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005531-28 Sponsor Protocol Number: Urso in Obese Start Date*: 2008-04-03
    Sponsor Name:Hanns-Ulrich Marschall
    Full Title: Ursodeoxycholic Acid in Morbidly Obese Patients Before Bariatric Surgery
    Medical condition: Patients with morbid obesity (MB) are investigated. MB is very frequently (90%) associated with non-alcoholic fatty liver disease (NAFLD) comprising a spectrum reaching from steatosis (NAFL) over s...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029530 Non-alcoholic fatty liver LLT
    Population Age: Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004978-22 Sponsor Protocol Number: OPHT-300920 Start Date*: 2021-01-21
    Sponsor Name:Medical University of Vienna, Department of Clinical Pharmacology
    Full Title: Detection of acetylsalicylic acid and omega-3 fatty acids in Schirmers’ test strips using mass spectrometry and correlations with tear film and blood flow parameters in healthy adults: an open-labe...
    Medical condition: Healthy subjects
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-001332-69 Sponsor Protocol Number: PG/04/100/17637 Start Date*: 2005-07-14
    Sponsor Name:University of Aberdeen
    Full Title: A randomised control trial of omega-3 fatty acid on platelet and endothelial function in patients with peripheral arterial disease
    Medical condition: Intermittent claudication
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-004402-55 Sponsor Protocol Number: 6344-001A Start Date*: 2020-11-09
    Sponsor Name:Baxter Healthcare Corporation
    Full Title: A Randomized, Double-Blind, Controlled, Clinical Trial to Evaluate the Risk of Developing Essential Fatty Acid Deficiency in Pediatric Patients, Including Neonates, Receiving Either Clinolipid (lip...
    Medical condition: Essential Fatty Acid Deficiency (EFAD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10015486 Essential fatty acid deficiency LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-015703-13 Sponsor Protocol Number: InReTel Start Date*: 2009-12-11
    Sponsor Name:Klinik für Innere Medizin II der Klinikum Chemnitz gGmbH
    Full Title: The influence of Telmisartan on insulin resistance and fatty liver in patients suffer from hypertension
    Medical condition: Influence of Telmisartan on insulin resistance, hypertension, non-alcoholic fatty liver
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020772 Hypertension LLT
    12.0 10052066 Metabolic syndrome LLT
    12.0 10022489 Insulin resistance LLT
    12.0 10016261 Fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004605-38 Sponsor Protocol Number: NUC-4/NAS Start Date*: 2015-02-11
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of norursodeoxycholic acid capsules with placebo in the treatment of non-alcoholic fatty liver di...
    Medical condition: Non-alcoholic fatty liver disease (NAFLD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004871 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000813-37 Sponsor Protocol Number: OCABSGS Start Date*: 2012-05-16
    Sponsor Name:Sahlgrenska Academy
    Full Title: Effects of obeticholic acid on hepatic fatty acid/triglyceride metabolism and hepatobiliary detoxification/elimination in morbidly obese and gallstone patients.
    Medical condition: Fatty liver disease, morbid obesity, gallstone disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003766-26 Sponsor Protocol Number: 25-12-59 Start Date*: 2009-10-12
    Sponsor Name:Southampton University Hospitals NHS Trust
    Full Title: The effects of purified n-3 fatty acids on serum biomarkers and cardiovascular risk markers in a randomized placebo controlled trial in patients with non alcoholic fatty liver disease
    Medical condition: Non alcoholic fatty liver disease (NAFLD). This fatty liver disease may progress to a chronic condition that sometimes deteriorates further to cirrhosis and even liver carcinoma. To date there is n...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10031743 Other chronic nonalcoholic liver disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003048-37 Sponsor Protocol Number: HSJC-CAR-01-2015 Start Date*: 2015-11-13
    Sponsor Name:Juan Luis Bonilla Palomas
    Full Title: Effect of ?-3 polyunsaturated fatty acids on serum albumin concentration in patients with acute heart failure, hypoalbuminemia, and high inflammatory activity
    Medical condition: Heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002656-32 Sponsor Protocol Number: HYPOTESIS Start Date*: 2013-07-23
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik für Innere Medizin III, Abt.f.Endokrinologie und Stoffwechsel
    Full Title: The impact of free fatty acid (FFA-) suppression on myocardial lipids and function in patients with type 2 diabetes
    Medical condition: type 2 diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004342-42 Sponsor Protocol Number: 201302 Start Date*: 2014-03-26
    Sponsor Name:Medisch Centrum Alkmaar
    Full Title: The effect of fish oil supplements on hemorheological parameters and walking distance in patients with intermittent claudication
    Medical condition: Patients suffering from intermittent claudication
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004866 10067825 Peripheral arterial disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-001975-36 Sponsor Protocol Number: 201200197536 Start Date*: 2012-05-24
    Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
    Full Title: Evaluation on the efficacy of docosahexaenoic acid for the treatment of nonalcoholic fatty liver disease in children
    Medical condition: Nonalcoholic steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003443-31 Sponsor Protocol Number: NUT-3/NAS Start Date*: 2019-06-10
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomised, placebo-controlled, phase IIb trial on the efficacy and safety of norursodeoxycholic acid tablets in patients with non-alcoholic steatohepatitis (NASH)
    Medical condition: Non-alcoholic steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing) GB (GB - no longer in EU/EEA) AT (Ongoing) HU (Ongoing) PL (Ongoing) ES (Ongoing) DE (Ongoing) LV (Completed) BE (Ongoing) GR (Prematurely Ended) NL (Ongoing) DK (Ongoing) PT (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002560-16 Sponsor Protocol Number: 747-303 Start Date*: 2015-12-10
    Sponsor Name:Intercept Pharmaceuticals Inc.
    Full Title: A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis
    Medical condition: Nonalcoholic steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004871 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) AT (Completed) SE (Completed) BE (Completed) DK (Completed) ES (Prematurely Ended) FI (Completed) PT (Prematurely Ended) HU (Completed) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-000645-12 Sponsor Protocol Number: GFT505-219-8 Start Date*: 2019-09-03
    Sponsor Name:GENFIT SA
    Full Title: A Double-Blind, Placebo-Controlled, Cross-over Phase II Study to Evaluate the Effect of a 6-week Elafibranor (120mg) treatment administered once daily on hepatic lipid composition in subjects with ...
    Medical condition: Subjects with Nonalcoholic Fatty Liver (NAFL)
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004871 10029530 Non-alcoholic fatty liver LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006424-18 Sponsor Protocol Number: EC/2006/117/PGMS Start Date*: 2007-03-01
    Sponsor Name:University of Surrey
    Full Title: THE EFFECT OF RIMONABANT ON ENERGY EXPENDITURE, FATTY ACID METABOLISM, TRIACYLGLYCEROL METABOLISM AND BODY FAT DISTRIBUTION
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029883 Obesity LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003537-18 Sponsor Protocol Number: 16-159 Start Date*: 2017-03-02
    Sponsor Name:Akershus University Hospital
    Full Title: The long-term effect of marine n-3 polyunsaturated fatty acid supplementation on glomerular filtration rate and development of fibrosis in the renal allograft: a randomized double blind placebo con...
    Medical condition: Renal transplantation.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002965-67 Sponsor Protocol Number: 57877.018.016 Start Date*: 2017-07-07
    Sponsor Name:AMC
    Full Title: An open, non-randomized, parallel-group pharmokinetic and -dynamic, investigator-initiated study on effects of obeticholic acid (OCA) in bile of patients with primary biliary cholangitis (PBC) and ...
    Medical condition: Primary biliairy cholangitis (PBC) Non-alcoholic steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10019805 Hepatobiliary disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000367-25 Sponsor Protocol Number: AURIGA Start Date*: 2019-04-17
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
    Full Title: Acute effect of parenteral rehydration solution commonly used in children with acute gastroenteritis on acid-base balance, free-fatty acids metabolism and glucose homeostasis
    Medical condition: Dehydration and metabolic acidosis due to acute gastroenteritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10012174 Dehydration PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 18 08:25:25 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA